T 1351/12 (Anti-CTLA-4 based immunotherapy/SQUIBB) of 16.07.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T135112.20180716
- Date of decision
- 16 July 2018
- Case number
- T 1351/12
- Petition for review of
- -
- Application number
- 04785793.3
- IPC class
- C07K 16/00A61P 35/00A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
- Applicant name
- E. R. Squibb & Sons, L.L.C.
- Opponent name
- -
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 11
- Keywords
- Main request - sufficiency of disclosure
Substantial procedural violation - (yes)
Remittal to the department of first instance (yes)
Reimbursement of appeal fee - (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division for further prosecution.
3. The appeal fee is reimbursed.